Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of H009 injection versus esomeprazole after endoscopic hemostasis for ulcer-related upper gastrointestinal bleeding
ChiCTR2400090869Phase 3Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of H009 and esomeprazole in upper gastrointestinal bleeding (UGIB) and Peptic ulcer disease (PUD), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Rate of no rebleeding within 72 hours after initiation of dosing. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
H009esomeprazole
03
Conditions
upper gastrointestinal bleeding (UGIB)Peptic ulcer disease (PUD)
Beyond the preview
Go deeper on ChiCTR2400090869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090869.